Navigation Links
Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
Date:2/8/2013

FRIDAY, Feb. 8 (HealthDay News) -- The cancer drug Avastin may extend the lives of patients with aggressive cervical cancer, a new study finds.

The findings might change the way these patients are treated and improve outcomes for women "who have previously had very limited treatment options," study lead researcher Dr. Krishnansu Tewari, said in a news release from the U.S. National Cancer Institute (NCI).

The research was sponsored by the NCI and received support from Genentech Inc., which makes Avastin.

The study included 452 women with recurrent, advanced or persistent cervical cancer that was not curable with standard chemotherapy. Patients who received Avastin with their chemotherapy lived an average of 17 months, compared with just over 13 months for those treated with chemotherapy alone, the investigators found.

The patients who received Avastin were given a dose of 15 milligrams per kilogram of body weight, which was administered in the vein with their chemotherapy treatment. The dose was given one day every three weeks until the patient's cancer progressed or levels of the drug in the body became too high.

Patients who received Avastin did have more side effects than those who didn't take the drug, the researchers noted, and the side effects were consistent with those known to be associated with Avastin -- events such as bleeding, clotting and gastrointestinal issues.

Avastin also comes with a hefty price tag, about $5,000 per month.

Still, the increase in survival seen with Avastin "is welcome news as progress has been very difficult against this cancer," Dr. Jeff Abrams, clinical director of NCI's Division of Cancer Treatment and Diagnosis, said in the news release.

Another expert not connected to the study agreed.

Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, noted that women with advanced cervical cancers that prove resistant to standard treatments "have traditionally been a very difficult group to treat effectively with regimens available." She said the new study "provides new opportunities to develop and further refine treatments for this group."

The data has been submitted for presentation in June at the annual meeting of the American Society of Clinical Oncology. Research that has not undergone peer review is typically considered preliminary until such review is completed.

More than 12,000 women will be diagnosed with cervical cancer in the United States in 2013 and over 4,000 women will die of the disease.

More information

The American Academy of Family Physicians has more about cervical cancer.

-- Robert Preidt

SOURCES: Elizabeth Poynor, M.D., gynecologic oncologist and pelvic surgeon, Lenox Hill Hospital, New York City; U.S. National Cancer Institute, news release, Feb. 7, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
2. Avastin Shows No Benefit for Earlier Colon Cancer: Study
3. Avastin Wont Extend Breast Cancer Survival: Study
4. Interpreting the Avastin-Lucentis study for persons with macular degeneration
5. Avastin No Benefit to Older Lung Cancer Patients: Study
6. More Fake Avastin Found in U.S., FDA Says
7. A Good Mood May Boost Seniors Brain Power
8. Living Near Equator May Boost Your Risk for Allergy, Asthma
9. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
10. Fried Foods May Boost Prostate Cancer Risk, Study Says
11. Plastic Surgery Practice Gets Boost from Lower Eyelid Surgery Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: